Article Text
DTB select
Spironolactone of no benefit in people with AF and HFpEF
Abstract
Overview of: Shantsila E, Shahid F, Sun Y, et al. Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. Efficacy Mech Eval 2020; 7(4).
- drug-related side effects and adverse reactions
- health care quality
- access
- and evaluation
Statistics from Altmetric.com
Footnotes
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.